MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530625 | Name: JTE-907
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JTE-907 is a drug used in scientific research that acts as a selective CB2 inverse agonist. It has antiinflammatory effects in animal studies,thought to be mediated by an interaction between the CB2 receptor and IgE.

Chemical Structure

JTE-907
JTE-907
CAS#282089-49-0

Theoretical Analysis

MedKoo Cat#: 530625

Name: JTE-907

CAS#: 282089-49-0

Chemical Formula: C24H26N2O6

Exact Mass: 438.1791

Molecular Weight: 438.48

Elemental Analysis: C, 65.74; H, 5.98; N, 6.39; O, 21.89

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 600.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
JTE-907; JTE 907; JTE907.
IUPAC/Chemical Name
N-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-Quinolinecarboxamide
InChi Key
GRAJFFFXJYFVOC-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H26N2O6/c1-3-4-5-10-30-22-19(29-2)9-7-16-12-17(24(28)26-21(16)22)23(27)25-13-15-6-8-18-20(11-15)32-14-31-18/h6-9,11-12H,3-5,10,13-14H2,1-2H3,(H,25,27)(H,26,28)
SMILES Code
O=C(C1=CC2=C(NC1=O)C(OCCCCC)=C(OC)C=C2)NCC3=CC=C(OCO4)C4=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
JTE-907 is a highly selective, orally active CB2 receptor inverse agonist and exerts anti-inflammatory effects in vivo.
In vitro activity:
JTE-907 (10, but not 1, mg/kg) and tacrolimus, but not betamethasone, tended to alleviate the dermatitis. Betamethasone inhibited the body weight gain. These results suggest that JTE-907 suppresses spontaneous itch-associated responses of NC mice without adverse effects such as weight loss. Reference: Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83. https://pubmed.ncbi.nlm.nih.gov/16824511/
In vivo activity:
Transient administration of the cannabinoid receptor 2 antagonist AM630 (10 mg/kg) or inverse agonist JTE907 (3 mg/kg) during immunization heightens the intensity and breadth of antigen-specific immune responses in young and aged mice through the upregulation of immunomodulatory genes in secondary lymphoid tissues. Reference: Sci Rep. 2017 Feb 17;7:42584. https://pubmed.ncbi.nlm.nih.gov/28209996/
Solvent mg/mL mM
Solubility
DMF 16.6 37.86
DMF:PBS (pH 7.2) (1:2) 0.2 0.46
DMSO 56.3 128.48
Ethanol 4.4 10.00
Methanol 1.0 2.28
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 438.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ruz-Maldonado I, Atanes P, Huang GC, Liu B, Persaud SJ. Direct Stimulatory Effects of the CB2 Ligand JTE 907 in Human and Mouse Islets. Cells. 2021 Mar 22;10(3):700. doi: 10.3390/cells10030700. PMID: 33809893; PMCID: PMC8004177. 2. Maekawa T, Nojima H, Kuraishi Y, Aisaka K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83. doi: 10.1016/j.ejphar.2006.05.040. Epub 2006 Jun 2. PMID: 16824511. 3. Dotsey E, Ushach I, Pone E, Nakajima R, Jasinskas A, Argueta DA, Dillon A, DiPatrizio N, Davies H, Zlotnik A, Crompton PD, Felgner PL. Transient Cannabinoid Receptor 2 Blockade during Immunization Heightens Intensity and Breadth of Antigen-specific Antibody Responses in Young and Aged mice. Sci Rep. 2017 Feb 17;7:42584. doi: 10.1038/srep42584. PMID: 28209996; PMCID: PMC5314369. 4. Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol. 2005 Sep 27;520(1-3):164-71. doi: 10.1016/j.ejphar.2005.08.013. PMID: 16153638.
In vitro protocol:
1. Ruz-Maldonado I, Atanes P, Huang GC, Liu B, Persaud SJ. Direct Stimulatory Effects of the CB2 Ligand JTE 907 in Human and Mouse Islets. Cells. 2021 Mar 22;10(3):700. doi: 10.3390/cells10030700. PMID: 33809893; PMCID: PMC8004177. 2. Maekawa T, Nojima H, Kuraishi Y, Aisaka K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83. doi: 10.1016/j.ejphar.2006.05.040. Epub 2006 Jun 2. PMID: 16824511.
In vivo protocol:
1. Dotsey E, Ushach I, Pone E, Nakajima R, Jasinskas A, Argueta DA, Dillon A, DiPatrizio N, Davies H, Zlotnik A, Crompton PD, Felgner PL. Transient Cannabinoid Receptor 2 Blockade during Immunization Heightens Intensity and Breadth of Antigen-specific Antibody Responses in Young and Aged mice. Sci Rep. 2017 Feb 17;7:42584. doi: 10.1038/srep42584. PMID: 28209996; PMCID: PMC5314369. 2. Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol. 2005 Sep 27;520(1-3):164-71. doi: 10.1016/j.ejphar.2005.08.013. PMID: 16153638.
1: Altun A, Yildirim K, Ozdemir E, Bagcivan I, Gursoy S, Durmus N. Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists. J Physiol Sci. 2015 Sep;65(5):407-15. doi: 10.1007/s12576-015-0379-2. Epub 2015 Apr 18. PubMed PMID: 25894754. 2: Marini P, Cascio MG, King A, Pertwee RG, Ross RA. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Br J Pharmacol. 2013 Jun;169(4):887-99. doi: 10.1111/bph.12191. PubMed PMID: 23711022; PubMed Central PMCID: PMC3687668. 3: Harvey BS, Nicotra LL, Vu M, Smid SD. Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine. 2013 Aug;63(2):209-17. doi: 10.1016/j.cyto.2013.04.032. Epub 2013 May 22. PubMed PMID: 23706402. 4: Franklin JM, Vasiljevik T, Prisinzano TE, Carrasco GA. Cannabinoid agonists increase the interaction between β-Arrestin 2 and ERK1/2 and upregulate β-Arrestin 2 and 5-HT(2A) receptors. Pharmacol Res. 2013 Feb;68(1):46-58. doi: 10.1016/j.phrs.2012.11.002. Epub 2012 Nov 19. PubMed PMID: 23174265; PubMed Central PMCID: PMC3562593. 5: González-Muniesa P, Bing C, Trayhurn P. Upregulation of the expression of inflammatory and angiogenic markers in human adipocytes by a synthetic cannabinoid, JTE-907. Horm Metab Res. 2010 Sep;42(10):710-7. doi: 10.1055/s-0030-1255119. Epub 2010 Jul 5. PubMed PMID: 20603779. 6: Morgan NH, Stanford IM, Woodhall GL. Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology. 2009 Sep;57(4):356-68. doi: 10.1016/j.neuropharm.2009.07.017. Epub 2009 Jul 16. PubMed PMID: 19616018. 7: Smid SD, Bjorklund CK, Svensson KM, Heigis S, Revesz A. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. Eur J Pharmacol. 2007 Dec 1;575(1-3):168-76. Epub 2007 Jul 26. PubMed PMID: 17706636. 8: Ueda Y, Miyagawa N, Wakitani K. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life Sci. 2007 Jan 9;80(5):414-9. Epub 2006 Sep 30. PubMed PMID: 17055000. 9: Maekawa T, Nojima H, Kuraishi Y, Aisaka K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83. Epub 2006 Jun 2. PubMed PMID: 16824511. 10: Raitio KH, Savinainen JR, Vepsäläinen J, Laitinen JT, Poso A, Järvinen T, Nevalainen T. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists. J Med Chem. 2006 Mar 23;49(6):2022-7. PubMed PMID: 16539390. 11: Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol. 2005 Sep 27;520(1-3):164-71. PubMed PMID: 16153638. 12: Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther. 2001 Feb;296(2):420-5. PubMed PMID: 11160626.

View History

HDAC6-IN-4b

HDAC6-IN-4b